

Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat

HUI Y. LAN, DAVID J. NIKOLIC-PATERSON, WEI MU, JAMES L. VANNICE, and ROBERT C. ATKINS

Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia, and Synergen, Boulder, Colorado, USA

Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat. The pathogenic role of interleukin-1 (IL-1) in the progression of established rat crescentic glomerulonephritis was investigated by administration of the interleukin-1 receptor antagonist (IL-1ra). Passive accelerated antglomerular basement membrane (GBM) disease was induced in three groups of six rats. One group was killed on day 7 with no treatment. The other groups received a constant infusion of IL-1ra or saline from day 7 until being killed on day 21. All animals developed moderate glomerular injury, a significant loss of renal function and marked histological damage including crescent formation by day 7. Saline treated animals showed a significant deterioration in these parameters over days 7 to 21. In contrast, animals treated with the IL-1ra over this period showed stabilization of glomerular injury (proteinuria; $P < 0.001$) and a recovery of normal renal function (creatinine clearance; $P < 0.05$). Histologically, IL-1ra treatment suppressed glomerular cell proliferation (PCNA expression; $P < 0.001$) and significantly inhibited crescent formation ($P < 0.005$), glomerular sclerosis ($P < 0.005$), tubular atrophy ($P < 0.05$) and interstitial fibrosis ($P < 0.05$). A key finding was that IL-1ra treatment not only stopped renal leukocyte accumulation over days 7 to 21 ($P < 0.01$), but that treatment also suppressed immune activation of the infiltrate ($P < 0.01$). In conclusion, this study provides direct evidence that IL-1 plays a key role in the progressive/chronic phase of renal injury in experimental crescentic glomerulonephritis and indicates that IL-1ra treatment may be of therapeutic benefit in human rapidly progressive crescentic glomerulonephritis.

Interleukin-1 (IL-1) is a cytokine which elicits a wide range of pro-inflammatory and immunologic effects, including: activation of endothelium; stimulation of T and B cell activation; up-regulation of leukocyte adhesion molecule expression by many cell types; and the induction of a range of cytokines and growth factors including interleukins 1, 2, 6 and 8, tumor necrosis factor- α , monocyte chemotactic protein-1, platelet-derived growth factor, and transforming growth factor- β , which regulate events such as leukocyte chemotaxis and the fibrotic response [1, 2]. A potential role for IL-1 in proliferative forms of glomerulonephritis was first suggested by studies in which macrophage-derived IL-1 was found to stimulate mesangial cell proliferation *in vitro* [3]. Since then, renal IL-1 production has been detected during acute and progressive/chronic phases of experimental [4-10] and human glomerulonephritis [11-13]. The main source of renal IL-1 production appears to be infiltrating macrophages

[5, 7, 10-13] which are a common feature of almost all forms of human and experimental glomerulonephritis [14], although other renal cell types such as mesangial cells and tubular epithelial cells can also synthesize IL-1 [12, 15].

To demonstrate a pathogenic role for IL-1 in glomerulonephritis it is necessary to block the action of IL-1 *in vivo*. Such an approach has been made possible by the identification and characterization of a specific IL-1 receptor antagonist (IL-1ra) [1, 16, 17]. Initial studies using the IL-1ra targeted acute glomerular injury in rat anti-GBM glomerulonephritis which is mediated by a transient glomerular neutrophil influx following deposition of antibodies on the GBM [18-20]. IL-1ra treatment during this period had no discernible effect upon neutrophil influx or glomerular injury. However, an important finding was that a 14 day treatment with the IL-1ra from the time of anti-GBM serum injection produced a marked suppression of the monocyte-dependent phase of glomerular injury and renal impairment [20]. Having demonstrated a key role for IL-1 in the induction of monocyte-dependent renal injury, the next question was whether blocking IL-1 could intervene in the progressive phase of established crescentic glomerulonephritis. This is an important issue because of its relevance to treatment of human disease and in identifying pathogenic mechanisms of renal damage, as a range of other mediators of renal injury are produced during the progressive phase. Hence, this study examined the ability of IL-1ra treatment to intervene in the progression of established rat anti-GBM glomerulonephritis.

Methods

Animals

Inbred male Sprague-Dawley rats (150 g) were obtained from the Monash University Animal House.

Nephrotoxic serum

Rabbit anti-rat GBM nephrotoxic serum was raised by repeated immunization of New Zealand white rabbits with particulate rat GBM, as previously described [21]. The anti-GBM serum was pooled, decomplexed and adsorbed extensively against normal rat erythrocytes.

Experimental design

Passive accelerated anti-GBM disease was induced in 18 rats as previously described [20, 22, 23]. Animals were immunized subcutaneously with 5 mg normal rabbit IgG in Freund's complete adjuvant and injected intravenously with 10 ml/kg body weight




Fig. 1. Suppression of renal injury by IL-1ra treatment. Data for (A) 24-hour urinary protein excretion, (B) plasma urea levels, (C) plasma creatinine levels, and (D) creatinine clearance are shown. Symbols are: saline treated animals (●), IL-1ra treated animals (○). Data are expressed as the mean \pm SEM for each experimental group of 6 animals. Untreated animals killed on day 7 of anti-GBM disease had proteinuria of 228 ± 25 mg/24 hr, plasma urea of 18.5 ± 1.2 mmol/liter, plasma creatinine of 72.5 ± 5.8 μ mol/liter, and creatinine clearance of 0.57 ± 0.08 ml/min. Statistical differences between untreated and IL-1ra treated groups was assessed by one way analysis of variance (ANOVA); * $P < 0.05$, ** $P < 0.001$.

rabbit anti-rat GBM serum (12.5 mg IgG/ml) five days later (termed day 0). One group of six rats was killed on day 7 with no treatment. The remaining animals received a constant infusion of either human recombinant IL-1ra (Synergen, Colorado, USA) or saline from day 7 until being killed at day 21 by means of an Alzet 2002 miniosmotic pump implanted under the skin of the back which delivered 0.5μ l/hr of 50 mg/ml IL-1ra in saline. Following pump implantation, all wounds healed cleanly and there were no signs of infection when pumps were removed at the end of the experiment.

Blood samples and 24-hour urine collections were taken on days 0, 7, 14, and 21. Plasma levels of hrIL-1ra were measured by a commercial ELISA (R&D Systems, MN, USA) and were 671 ± 175 ng/ml (mean \pm SEM) on day 14 and 643 ± 112 ng/ml on day 21. In addition, one group of six normal rats was also examined.

Analysis of renal function and proteinuria

Urinary protein excretion was determined using the Manual Ponceau Red method. Urinary blood (hematuria) was determined by a standard Combur's stick test (Boehringer Mannheim) and semi-quantitated into four scores: (1) trace or minor, (2) mild, (3) moderate, and (4) severe. Concentrations of plasma and urine creatinine were measured using the standard Jaffe rate reaction (alkaline picrate), while plasma urea concentrations were measured by the NED/OPA assay. All analyses were performed in the Department of Biochemistry, Monash Medical Centre.

Immunofluorescence

Tissues for direct immunofluorescence staining were frozen in liquid nitrogen and 6μ m cryostat sections were stained with fluorescein isothiocyanate (FITC)-conjugated goat polyclonal antibodies to rat IgG, C3 and fibrinogen or FITC-conjugated sheep anti-rabbit IgG (Nordic, the Netherlands). The intensity of antibody staining was semi-quantitatively assessed as: nil (0), mild (+), moderate (++), and strong (+++). In addition, day 21 tissues were assessed for deposition of immune reactants by

semi-quantitative immunofluorescence staining using a blinded antibody titration method as previously described [23]. Briefly, consecutive cryostat sections from each animal were incubated with serial dilutions of FITC-conjugated antibodies against rabbit IgG, rat IgG or rat C3. Blinded sections were examined on the same day and the titer at which antibody staining became undetectably scored. Results are expressed in terms of mean \pm SEM of the inverse antibody titer for groups of six animals.

Measurement of plasma antibodies

Plasma levels of rabbit IgG, rat anti-rabbit IgG, rat anti-human rIL-1ra IgG and total rat IgG were determined by capture ELISA as previously described [23]. Briefly, 96-well ELISA plates were coated with 100μ l of swine anti-rabbit IgG, normal rabbit IgG, human recombinant IL-1ra or normal rat IgG (10μ g/ml in 0.1 M carbonate-bicarbonate buffer, pH 9.0) overnight at 4° C, blocked with 2% bovine serum albumin and washed ($\times 4$) with 0.05% Tween 20 in PBS. Triplicate serum samples (1:1000 dilution) were added to wells, incubated for two hours and washed ($\times 4$) with 0.05% Tween 20 in PBS. Bound rabbit or rat IgG was detected using a peroxidase-conjugated sheep anti-rabbit IgG or peroxidase-conjugated sheep anti-rat IgG (Sigma Chemical Co., St. Louis, MO, USA) and color development with the OPD substrate for 10 minutes in the dark. The reaction was terminated with 3 M H_2SO_4 and optical density (OD) was read at 490 nm on a Dynatec MR 5000 ELISA plate reader. The background reading obtained with normal rat serum, which was the same as the buffer blank, was subtracted from the readings, except for measurement of total rat IgG when the buffer blank was subtracted.

Histopathology

Tissues for histology were fixed in formalin and 4μ m paraffin sections were stained with hematoxylin and eosin or periodic acid-Schiff. Glomerular and tubulointerstitial damage was scored as follows: the percentage of glomeruli exhibiting atrophy/segmental sclerosis, global sclerosis or glomerular crescent formation

was assessed by examination of at least 100 glomerular cross sections per animal in periodic acid-Schiff-stained sections. Glomerular hypercellularity was assessed on the basis of total glomerular cell counts/glomerular cross section (gcs). At least 100 glomeruli per animal were scored in hematoxylin and eosin-stained sections and ranked as follows: (0), normal (less than 50 cells/gcs); (1), mild (60 to 80 cells/gcs); (2), moderate (80 to 120 cells/gcs); (3), severe hypercellularity (more than 120 cells/gcs).

Tubulointerstitial lesions of tubular atrophy and fibrosis were semi-quantitatively analyzed on hematoxylin and eosin-stained sections and graded on a scale of 0 to 3 as follows: (0) no apparent damage; (1) mild damage, with lesions involving less than 15% of the cortex; (2) moderate damage, involving 15 to 30% of the cortex; and (3) severe damage, that is, involving more than 30% of the cortex and focal accumulation of leukocytes at sites of damage.

Immunoperoxidase staining

Monoclonal antibodies (mAb) used for immunoperoxidase staining were as follows: OX-1, leukocyte common antigen [24]; ED1, monocytes, macrophages and some dendritic cells [25]; R73, non-polymorphic $\alpha\beta$ T cell receptor [26]; OX-8, anti-rat CD8, cytotoxic T lymphocytes and NK cells [27]; F17-23-2, MHC class II Ia antigen (RT1-B) [28]; NDS-61, p55 chain of the interleukin-2 receptor (IL-2R) [29]; PC-10, proliferating cell nuclear antigen (PCNA) [30].

Tissues for immunoperoxidase staining were fixed in 2% paraformaldehyde-lysine-periodate and serial 6 μ m cryostat sections were labeled with monoclonal antibodies (mAbs) using a standard three layer peroxidase-anti-peroxidase method and developed with diaminobenzidine as previously described [20, 22]. Three layer immunoperoxidase staining with the PC-10 mAb was performed on cryostat tissue sections which were pre-treated with microwave oven heating for 2×5 minutes in 0.01 M sodium citrate pH 6.0 at 800 watts as previously described [31, 32]. This treatment facilitates antigen retrieval, thereby increasing the sensitivity of PCNA detection.

Quantitation of leukocytes in tissue sections

Leukocyte subpopulations infiltrating the glomerulus and interstitium were analyzed by mAb labeling of cryostat tissue sections. Cells labeled by each mAb were counted in high power fields ($\times 400$) of 20 consecutive glomeruli for each animal (this minimized variation in cell counts caused by differences in glomerular cross section areas). The mean of 20 glomerular counts from each group of six animals was expressed as cells \pm standard error of mean (SEM) per glomerular cross section. To assess tubulointerstitial leukocyte infiltration, cortical areas were selected at random. The number of labeled cells was assessed from 20 consecutive high power fields by means of a 0.02 mm² graticule fitted in the eyepiece of the microscope. These fields progressed from the outer to inner cortex, avoiding only large vessels, glomerular and immediate periglomerular areas. For each tissue, the same area was examined in serial sections labeled with different mAbs. No adjustment of the cell count was made for tubules or the luminal space. The mean of 20 field counts from each group of six animals was expressed as cells per mm² \pm SEM.

Scoring of histological changes, immunofluorescence and immunoperoxidase staining was performed on coded slides by an experienced renal pathologist (HYL).




Fig. 2. Effect of IL-1ra treatment on the plasma antibody levels. Plasma levels of (A) rabbit IgG, and (B) rat anti-rabbit IgG, were quantitated at different times by ELISA. Symbols are: saline treated animals (●); IL-1ra treated animals (○). Data are expressed as the mean optical density (OD₄₉₀) \pm SEM for each group of 6 animals with background subtracted. Untreated animals killed on day 7 had 0.85 \pm 0.04 and 0.04 \pm 0.05 OD₄₉₀ plasma rabbit IgG and 0.05 \pm 0.05 and 0.44 \pm 0.13 OD₄₉₀ plasma rat anti-rabbit IgG on days 1 and 7, respectively.

Statistical analysis

Data from the measurement of renal function and proteinuria over the experimental course were analyzed using the one way analysis of variance (ANOVA) program from Complete Statistical System (CSS, Statsoft, USA), and individual time points were also compared using the unpaired *t*-test. Data from leukocyte infiltration in the two renal compartments was compared using an unpaired *t*-test. Measurements of hematuria and histological changes were compared by the non-parametric Mann-Whitney *U* test.

Results

Renal function and proteinuria

On day 7 of anti-GBM disease, all animals exhibited moderate proteinuria, a significant increase in plasma levels of creatinine and urea, and a 37% reduction in creatinine clearance (Fig. 1). Over days 7 to 21 there was a significant deterioration in saline

Table 1. Inhibition of histopathological damage by IL-1ra treatment

	Glomerulus							Tubulointerstitium	
	Hypercellularity %			PCNA ⁺ cell/gcs	Sclerosis %		Crescents %	Atrophy (0-3)	Fibrosis (0-3)
	+	++	+++		Segmental	Global			
Untreated Day 7	25.3 ± 2.4	24.5 ± 1.6	10.3 ± 1.5	12.8 ± 1.2	21.0 ± 3.8	0.6 ± 0.2	14.0 ± 3.2	1.2 ± 0.2	1.5 ± 0.2
Saline treated Day 21	16.7 ± 3.2 ^a	44.5 ± 3.6 ^b	29.5 ± 6 ^a	12.0 ± 0.9	49.0 ± 5.1 ^b	13.8 ± 5.8 ^b	58.5 ± 4.9 ^b	2.8 ± 0.2 ^a	2.7 ± 0.2 ^a
IL-1ra treated Day 21	18.2 ± 1.4 ^a	25.0 ± 3.5 ^b	13.5 ± 2.3	5.8 ± 0.6 ^{bc}	24.5 ± 3.6 ^a	3.2 ± 1.1 ^a	25.0 ± 4.0 ^b	1.3 ± 0.2 ^b	1.5 ± 0.2 ^a

^a $P < 0.05$, ^b $P < 0.005$, compared to untreated day 7 animals, ^c $P < 0.001$, compared to saline treated day 21 animals

treated animals which developed severe proteinuria, a further increase in plasma levels of creatinine and urea, while creatinine clearance remained impaired (Fig. 1). This is consistent with previous studies in this model in which a very similar disease progression was evident in untreated animals over this time course [22, 23].

IL-1ra treatment over days 7 to 21 prevented the increase in proteinuria seen in saline treated animals, stabilized plasma creatinine and reduced plasma urea to normal levels (Fig. 1). Of particular note was the finding that IL-1ra treatment produced a gradual recovery to a normal rate of creatinine clearance (Fig. 1D).

On day 7 of anti-GBM disease, all animals exhibited moderate to severe hematuria (2.3 ± 0.8). In saline treated animals, there was an increase in hematuria over days 7 to 21 (3.0 ± 0.4 on day 21). However, IL-1ra treatment resulted in a marked improvement in hematuria with all animals showing only trace to mild hematuria on day 21 (1.0 ± 0 ; $P < 0.05$ vs. saline treated).

Deposition of immune reactants

Deposition of immune reactants within the kidney was assessed by direct immunofluorescence staining of cryostat tissue sections. In untreated animals killed on day 7 of anti-GBM disease, there was strong (+++) linear deposition of rabbit IgG and moderate (++) linear deposition of rat IgG, and C3 along the GBM. In addition, moderate (++) fibrinogen deposition was seen within Bowman's space in some glomeruli and within the interstitium. At day 21, saline treated animals exhibited strong (+++) linear deposition of rabbit IgG, rat IgG and C3 along the GBM. There was also a strong patchy deposition of fibrinogen, rat IgG and C3 within Bowman's space, crescents and necrotic glomerular capillary tufts and strong fibrinogen deposition throughout the interstitium.

The effect of IL-1ra treatment on the intensity of immune deposits on the GBM on day 21 of anti-GBM disease was assessed by a serial dilution immunofluorescence technique as described in the Methods section. There was no difference in the intensity of rabbit IgG deposition on the GBM in saline treated and IL-1ra treated animals (12000 ± 1454 vs. 12800 ± 1905 ; mean inverse antibody titer \pm SEM, respectively). Similarly, there was no difference in the intensity of rat IgG deposition (900 ± 73 vs. 940 ± 39) or C3 deposition (4800 ± 762 vs. 3290 ± 953) in saline and IL-1ra treated animals, respectively. However, IL-1ra treated animals showed little, if any, deposition of rat IgG, C3 and fibrinogen

within Bowman's space and had only mild (+) fibrinogen deposition throughout the interstitium.

Quantitation of plasma antibody titers by ELISA was performed to check that all animals received an equivalent dose of rabbit anti-GBM serum and to examine whether IL-1ra treatment had any suppressive effect on the humoral immune response. Figure 2A shows that high plasma levels of rabbit IgG were still evident 24 hours after injection of anti-GBM serum and had almost disappeared by day 7. There was no difference in plasma rabbit IgG levels in any of the experimental groups. The time course of the rat anti-rabbit IgG response is shown in Figure 2B. Rat anti-rabbit IgG was detected on day 1 reflecting the fact that these animals were primed with rabbit IgG. There was a fourfold increase in rat anti-rabbit IgG levels on day 7 and the response remained at this level to day 21. No differences in rat anti-rabbit IgG levels were apparent between the saline and IL-1ra treated groups. Similarly, there was no difference in plasma levels of total rat IgG on day 21 (0.566 ± 0.017 vs. 0.577 ± 0.024 OD₄₉₀ in saline and IL-1ra treated animals respectively; $P = \text{NS}$). Of note was a small antibody response to the administered human IL-1ra on day 21 (0.013 ± 0.004 OD₄₉₀) which was absent in saline treated animals.

Histopathology

A detailed evaluation of renal histopathology was made on all three groups of animals (Table 1). On day 7 of anti-GBM disease, untreated animals displayed significant renal lesions. These untreated animals exhibited mild to severe hypercellularity in 60% of glomeruli and there was marked glomerular cell proliferation as assessed by PCNA expression (12.8 ± 1.2 vs. 2.0 ± 1.8 PCNA⁺ cells/gcs in normal rats; $P < 0.01$). Segmental glomerular sclerosis and crescent formation were also evident on day 7 of disease as was mild tubular atrophy and fibrosis (Table 1). In saline treated animals, there was a pronounced deterioration in renal histopathology by day 21 of the disease. Both the percentage and severity of glomerular hypercellularity increased while the number of PCNA⁺ glomerular cells remained high. In addition, there was a marked increase in glomerular segmental and global sclerosis and crescent formation as well as severe tubular atrophy and fibrosis.

Renal histopathology changes between IL-1ra and saline treatment animals at day 21. IL-1ra treatment essentially halted deterioration of renal histopathology over the days 7 to 21 period (Table 1). The percentage of hypercellular glomeruli and the severity of glomerular hypercellularity was similar in IL-1ra




Fig. 3. Suppression of renal leukocytic infiltration and immune-activation by IL-1ra treatment. Total leukocytes and leukocyte subsets were analyzed by labeling serial tissue sections with mAbs. Abbreviations are: OX-1, total leukocytes; ED1, macrophages; R73, total T cells; F.17.23.2, MHC class II I-A antigen; NDS 61, IL-2R. (a) Quantitation of leukocyte infiltration in the glomerulus. (b) Quantitation of leukocyte infiltration in the tubulointerstitium. Data are expressed as the mean \pm SEM for each group of 6 animals. Open bars represent untreated day 7 anti-GBM disease. Closed bars represent day 21 saline treated animals. Hatched bars represent day 21 IL-1ra treated animals. Data for antibody labeling of normal rat glomeruli are as follows: 0.94 ± 0.10 OX-1⁺ cells/gcs; 0.76 ± 0.10 ED1⁺ cells/gcs; 0.34 ± 0.10 R73⁺ cells/gcs; 1.1 ± 0.21 F.17.23.2⁺ cells/gcs; 0 ± 0 NDS 61⁺ cells/gcs. Data for antibody labeling of normal rat interstitium are as follows: 99.4 ± 10.2 OX-1⁺ cells/mm²; 26.0 ± 1.4 ED1⁺ cells/mm²; 31.4 ± 6.7 R73⁺ cells/mm²; 99.0 ± 7.0 F.17.23.2⁺ cells/mm²; 0 ± 0 NDS 61⁺ cells/mm². Statistical differences between the different groups was assessed by unpaired *t*-test: * *P* < 0.05, ** *P* < 0.01, *** *P* < 0.001, or not significant (NS).

treated animals at day 21 and untreated animals at day 7, while glomerular cell proliferation was markedly inhibited by IL-1ra treatment (Table 1). Glomerular segmental and global sclerosis and crescent formation were not different in IL-1ra treated animals compared to untreated animals at day 7. Similarly, tubular atrophy and interstitial fibrosis were also unchanged. An example of histological damage in an IL-1ra treated animals is shown in Figure 3b.

Glomerular leukocytic infiltration

Renal leukocytic accumulation and immune activation was examined by mAb labeling of cryostat tissue sections. There was a

prominent glomerular leukocyte infiltrate on day 7 of anti-GBM disease (11.4 ± 1.3 vs. 1.1 ± 0.2 OX-1⁺ cells/gcs in normal rats; *P* < 0.001) which was composed of ED1⁺ macrophages (Fig. 3a). There was no significant increase in glomeruli R73⁺ T cells (Fig. 3a) or CD8⁺ cells (0.53 ± 0.1 vs. 0.24 ± 0.1 CD8⁺ cells/gcs in normal; *P* = NS), although there was an increase in the number of CD4⁺ cells (3.47 ± 0.3 vs. 0.56 ± 0.12 CD4⁺ cells/gcs in normal; *P* < 0.05) which presumably reflects a subpopulation of CD4⁺ macrophages. There was also a significant increase in the number of glomerular cells expressing MHC class II antigens (5.1 ± 0.6 vs. 1.2 ± 0.2 MHC class II⁺ cells/gcs in normal rats; *P* < 0.05) which may be "activated" macrophages or mesangial cells.

In saline treated animals, there was no significant change in the pattern of glomerular leukocytic infiltration or MHC class II expression over days 7 to 21 (Fig. 3a). However, IL-1ra treatment over this period significantly reduced glomerular macrophage infiltration in comparison to saline treated animals (Fig. 3a).

Interstitial leukocytic infiltration

The composition of interstitial leukocytic infiltration was different to that seen in the glomerulus (Fig. 3). On day 7 of anti-GBM disease there was a significant interstitial leukocyte infiltrate (735 ± 81 vs. 102 ± 16 OX-1⁺ cells/mm² in normal rats; *P* < 0.001) which was composed of both ED1⁺ macrophages and R73⁺ T cells. There was evidence of immune activation of the mononuclear cell infiltrate as shown by interleukin-2 receptor (IL-2R) expression and the prominent accumulation of MHC class II⁺ cells within the interstitium (Fig. 3b). The T cell infiltrate contained both CD8⁺ cells (109 ± 8.5 at day 7 vs. 38.0 ± 8.0 CD8⁺ cells/gcs in normal; *P* < 0.05) and CD4⁺ cells (570.5 ± 94 vs. 92.0 ± 23.8 CD4⁺ cells/gcs in normal; *P* < 0.01), although many macrophages also expressed the CD4 antigen.

There was a significant increase in the number of interstitial ED1⁺ macrophages and R73⁺ T cells in saline treated animals over days 7 to 21. Of particular note was the marked increase in the number of immune-activated mononuclear cells—both IL-2R⁺ cells ($\uparrow 283\%$) and MHC class II⁺ cells ($\uparrow 111\%$)—during this period. Many of these activated cells were seen in focal infiltrates of T cells and macrophages around and within damaged tubules and immediately adjacent to areas of Bowman's capsule rupture. However, there was no change in the number of CD8⁺ cells (109 ± 8.5 at day 7 vs. 103 ± 9.4 CD8⁺ cells/mm² at day 21; *P* = NS) while the number of CD4⁺ cells was increased (570.5 ± 94 at day 7 vs. 846.5 ± 41 CD4⁺ cells/mm² at day 21; *P* < 0.01). This indicated that the increased number of R73⁺ T cells seen in saline treated animals was due to accumulation of CD4⁺ T cells.

IL-1ra treatment completely stopped interstitial leukocyte accumulation and immune activation over the 7 to 21 day period (Fig. 3b). The suppression of aggressive focal leukocytic infiltrates was associated with a marked reduction in tubular damage and interstitial fibrosis.

Discussion

This study has evaluated the effect of IL-1ra treatment on the progression of established rat accelerated anti-GBM disease—a severe model of glomerulonephritis which exhibits many features similar to that of human rapidly progressive glomerulonephritis. In this model, significant glomerular injury, renal function impairment and histological damage was evident on day 7 which rapidly progressed to a severe form of crescentic glomerulonephritis by

day 21. IL-1ra treatment over days 7 to 21 halted the progression of established disease as demonstrated by: (i) stabilization of proteinuria and reduction of hematuria, (ii) reversal of renal function impairment, and (iii) inhibition of renal histopathological damage. The ability of IL-1ra treatment to intervene and halt disease progression in this model demonstrates a key pathogenic role for IL-1 in crescentic glomerulonephritis. Indeed, the ability to halt disease progression by targeting just one cytokine is most impressive considering that a range of other cytokines and mediators of renal injury are also produced during the disease process [33]. This argues that the cytokine network *in vivo* operates in an interdependent fashion rather than exhibiting functional redundancy as suggested by their many overlapping functions *in vitro*.

The suppression of rat anti-GBM disease by IL-1ra treatment indicates that IL-1 acts at several levels in disease pathogenesis. Possible mechanisms of IL-1ra mediated suppression of disease progression are discussed below.

T cells and macrophages play a crucial role in the induction and progression of experimental anti-GBM disease [22, 34–38]. Glomerular macrophages are associated with glomerular hypercellularity, crescent formation and glomerulosclerosis, while in the interstitium aggressive focal accumulation of activated T cells (IL-2R+) and macrophages is associated with tubular atrophy, Bowman's capsule rupture, granuloma formation and interstitial fibrosis. This disease is different to the NK (CD8+) cell-dependent anti-GBM disease induced in the susceptible WKY rat strain [39], as it features a progressive accumulation and activation of CD4+ T cells within the interstitium, while CD8+ cell numbers do not change during disease progression over days 1 to 21 [22]. The ability of IL-1ra treatment of established anti-GBM disease to reduce glomerular macrophage accumulation compared to saline treated animals and to completely halt interstitial T cell and macrophage accumulation and activation over this period was associated with the stabilization of glomerular injury and the cessation of histological damage. This suppression of leukocyte infiltration and activation is consistent with previous studies in which IL-1ra treatment prevented the development of glomerular, and in particular, interstitial leukocyte infiltration during the induction phase of rat anti-GBM disease by suppressing up-regulation of renal ICAM-1 (CD54) expression [20, 40].

Glomerular hypercellularity is a feature of proliferative forms of glomerulonephritis and results from an increased number of mesangial cells and glomerular leukocyte infiltration [41]. The use of double immunohistochemistry staining has demonstrated that most glomerular PCNA+ cells detected in human and experimental models of glomerulonephritis are proliferating mesangial cells [41, 42]. In our study, IL-1ra treatment appeared to suppress glomerular hypercellularity through inhibition of mesangial cell proliferation as evidenced by the marked reduction in the number of glomerular PCNA+ cells. This could be a direct effect since IL-1 is a mesangial cell growth factor *in vitro* [3]. However, IL-1ra treatment could also act indirectly through suppression of production of other mesangial cell growth factors such as IL-6 or platelet-derived growth factor (PDGF) by mesangial cells or infiltrating macrophages [31, 43].

One further mechanism by which blocking IL-1 action could inhibit rat anti-GBM disease is through modulation of the humoral immune response. In this model, there is a strong systemic immune response to the immunizing rabbit IgG and the subse-

quent challenge with rabbit nephrotoxic serum [44]. Semi-quantitative immunofluorescence staining found that IL-1ra treatment had no effect upon the deposition of rabbit IgG, rat IgG or C3 on the GBM. In addition, IL-1ra treatment had no measurable effect upon plasma levels of rat anti-rabbit IgG antibody throughout the disease course. Thus, blocking IL-1 did not affect the systemic humoral immune response. Indeed, a mild antibody response to the administered human IL-1ra was detected, consistent with a report that the IL-1ra does not inhibit antigen specific responses *in vivo* [45].

Further studies of established experimental crescentic glomerulonephritis are warranted to determine: (1) whether disease remains suppressed when IL-1ra treatment is stopped, and (2) how rapidly IL-1ra treatment is able to halt disease progression.

In conclusion, this study provides the first direct evidence that IL-1 plays a key pathogenic role in the progressive/chronic phase of renal injury in experimental crescentic glomerulonephritis. This study also demonstrates the therapeutic potential of the IL-1ra for treatment of human rapidly progressive glomerulonephritis.

Acknowledgments

This work was funded in part by an NH&MRC grant (#930825) and a grant from the Baxter Extramural Grant Program. The NDS 61 cell line was the kind gift of Dr. M. Dallman, University of Oxford. Part of this work was presented at the 30th meeting of the Australia and New Zealand Society of Nephrology, Adelaide, 1994. We acknowledge the assistance of Song Qing with the ELISA studies.

Reprint requests to Robert C. Atkins, M.D., Department of Nephrology, Monash Medical Centre, Clayton, Victoria 3168, Australia.

References

1. DINARELLO CA: Interleukin-1 and interleukin-1 antagonism. *Blood* 77:1627–1652, 1991
2. DINARELLO CA, WOLFF SM: The role of interleukin-1 in disease. *N Engl J Med* 328:106–113, 1993
3. LOVETT DH, RYAN JL, STERZEL B: Stimulation of rat mesangial cell proliferation by macrophage interleukin-1. *J Immunol* 131:2830–2836, 1983
4. MATSUMOTO K, ATKINS RC: Glomerular cells and macrophages in the progression of experimental focal glomerulosclerosis. *Am J Pathol* 134:933–945, 1989
5. BOSWELL JM, YUI MA, BURT DW, KELLEY VE: Increased tumor necrosis factor and IL-1 β gene expression in the kidneys of mice with lupus nephritis. *J Immunol* 141:3050–3054, 1988
6. MATSUMOTO K, HATANO M: Production of interleukin-1 in glomerular cultures from rats with nephrotoxic serum nephritis. *Clin Exp Immunol* 75:123–128, 1989
7. MATSUMOTO K: Production of interleukin-1 by glomerular macrophages in nephrotoxic serum nephritis. *Am J Nephrol* 10:502–506, 1990
8. CAMUSSI G, TETTA C, BUSSOLINO F, TURELLO E, BRENTJENS J, MONTRUCCHIO G, ANDRES G: Effect of leukocyte stimulation on rabbit immune complex glomerulonephritis. *Kidney Int* 38:1047–1055, 1990
9. DIAMOND JR, PESEK I: Glomerular tumor necrosis factor and interleukin 1 production during acute aminonucleoside nephrosis. *Lab Invest* 64:21–28, 1991
10. TIPPING PG, LOWE MG, HOLDSWORTH SR: Glomerular interleukin-1 production is dependent on macrophage infiltration in anti-GBM glomerulonephritis. *Kidney Int* 39:103–110, 1991
11. MATSUMOTO K, DOWLING J, ATKINS RC: Production of interleukin-1 in glomerular cell cultures from patients with rapidly progressive crescentic glomerulonephritis. *Am J Nephrol* 8:463–470, 1988
12. NORONHA IL, KRUGER C, ANDRASSY K, RITZ E, WALDHERR R: In situ production of TNF- α , IL-1 β and IL-2R in ANCA-positive glomerulonephritis. *Kidney Int* 43:682–692, 1993
13. YOSHIOKA K, TAKEMURA T, MURAKAMI K, OKADA M, YAGI K,

- MIYAZATO H, MATSUSHIMA K, MAKI S: In situ expression of cytokines in IgA nephritis. *Kidney Int* 44:825-833, 1993
14. NIKOLIC-PATERSON DJ, LAN HY, HILL PA, ATKINS RC: Macrophages in renal injury. *Kidney Int* 45 (Suppl 45):S79-S82, 1994
 15. LOVETT DH, LARSEN A: Cell-cycle-dependent interleukin-1 gene expression by cultured glomerular mesangial cells. *J Clin Invest* 82:115-122, 1988
 16. EISENBERG SP, EVANS RJ, AREND WP, VERDERBER E, BREWER MT, HANNUM CH, THOMPSON RC: Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. *Nature* 343:341-346, 1990
 17. DINARELLO CA, THOMPSON RC: Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. *Immunol Today* 12:404-410, 1991
 18. MULLIGAN MS, JOHNSON KJ, TODD III RF, ISSEKUTZ TB, MIYASAKA M, TAMATANI T, SMITH CW, ANDERSON DC, WARD PA: Requirements for leukocyte adhesion molecules in nephrotoxic nephritis. *J Clin Invest* 91:577-587, 1993
 19. TANG WW, FENG L, VANNICE JL, WILSON CB: Interleukin-1 receptor antagonist ameliorates experimental anti-glomerular basement membrane antibody-associated glomerulonephritis. *J Clin Invest* 93:273-279, 1994
 20. LAN HY, NIKOLIC-PATERSON DJ, ZARAMA M, VANNICE JL, ATKINS RC: Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist. *Kidney Int* 43:479-485, 1993
 21. HOLDSWORTH SR, THOMSON NM, GLASGOW EF, DOWLING JP, ATKINS RC: Tissue culture of isolated glomeruli in experimental crescentic glomerulonephritis. *J Exp Med* 147:98-109, 1978
 22. LAN HY, PATERSON DJ, ATKINS RC: Initiation and evolution of interstitial leukocytic infiltration in experimental glomerulonephritis. *Kidney Int* 40:425-433, 1991
 23. LAN HY, ZARAMA M, NIKOLIC-PATERSON DJ, KERR PG, ATKINS RC: Suppression of experimental crescentic glomerulonephritis by deoxyspergualin. *J Am Soc Nephrol* 3:1765-1774, 1993
 24. SUNDERLAND CA, MCMASTER WR, WILLIAMS AF: Purification with monoclonal antibody of a predominant leukocyte-common antigen and glycoprotein from rat thymocytes. *Eur J Immunol* 9:155-159, 1979
 25. DIJKSTRA CD, DOPP EA, JOLING P, KRAAL G: The heterogeneity of mononuclear phagocytes in lymphoid organs: Distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2, ED3. *Immunology* 54:589-599, 1985
 26. HUING T, WALLNY HJ, HARTLEY JK, LAWETZKY A, TIEFENTHALER G: A monoclonal antibody to a constant region determinant of the rat T cell antigen receptor that induces T cell activation. *J Exp Med* 169:73-86, 1989
 27. BRIDEAU RJ, CARTER PB, MCMASTER WR, MASON DW, WILLIAMS AF: Two subsets of rat T lymphocytes defined with monoclonal antibodies. *Eur J Immunol* 10:609-615, 1980
 28. HART DNJ, FABRE JW: Endogenously produced Ia antigens within cells of convoluted tubules or rat kidney. *J Immunol* 126:2109-2113, 1981
 29. TELLIDES G, DALLMAN MJ, MORRIS PJ: Mechanism of action of interleukin-2 receptor (IL-2R) monoclonal antibody (MAb) therapy: Target cell depletion or inhibition of function? *Transplant Proc* 21:997-998, 1989
 30. WASEEM NH, LANE DP: Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). *J Cell Sci* 96:121-129, 1990
 31. SHI S-R, CHAIWUN B, YOUNG L, COTE RJ, TAYLOR CR: Antigen retrieval technique utilizing citrate buffer or urea solution for immunohistochemical demonstration of androgen receptor in formalin-fixed paraffin sections. *J Histochem Cytochem* 41:1599-1604, 1993
 32. LAN HY, MU W, NIKOLIC-PATERSON DJ, ATKINS RC: A novel, simple, reliable and sensitive method of multiple immunoenzymic staining: Use of microwave oven heating to block antibody cross-reactivity and retrieve antigens. *J Histochem Cytochem* 43:97-102, 1995
 33. SEDOR JR: Cytokines and growth factors in renal injury. *Semin Nephrol* 12:428-440, 1992
 34. LAN HY, NIKOLIC-PATERSON DJ, ATKINS RC: Involvement of activated periglomerular leucocytes in the rupture of Bowman's capsule and crescent progression in experimental glomerulonephritis. *Lab Invest* 67:743-751, 1992
 35. SCHREINER GF, COTRAN RS, PARDO V, UNANUE ER: A mononuclear cell component to experimental immunological glomerulonephritis. *J Exp Med* 147:369-384, 1978
 36. HOLDSWORTH SR, NEALE TJ: Macrophage induced glomerular injury: Cell transfer studies in passive autologous antiglomerular basement membrane antibody-initiated experimental glomerulonephritis. *Lab Invest* 51:172-180, 1984
 37. HUANG XR, HOLDSWORTH SR, TIPPING PG: Evidence for delayed-type hypersensitivity mechanisms in glomerular crescent formation. *Kidney Int* 46:69-78, 1994
 38. MAIN IW, NIKOLIC-PATERSON DJ, ATKINS RC: T Cells and macrophages and their role in renal injury. *Semin Nephrol* 12:428-440, 1992
 39. KAWASAKI K, YAOITA E, YAMAMOTO T, KIHARA I: Depletion of CD8 positive cells in nephrotoxic serum nephritis of WKY rats. *Kidney Int* 41:1517-1526, 1992
 40. NIKOLIC-PATERSON DJ, LAN HY, HILL PA, VANNICE JL, ATKINS RC: Interleukin-1 receptor antagonist inhibits ICAM-1 upregulation and leukocyte infiltration in experimental glomerulonephritis. *J Am Soc Nephrol* 4:1695-1700, 1994
 41. JOHNSON RJ: The glomerular response to injury: Progression or resolution? *Kidney Int* 45:1769-1782, 1994
 42. ALPERS CE, HUDKINS KL, GOWN AM, JOHNSON RJ: Enhanced expression of "muscle-specific" actin in glomerulonephritis. *Kidney Int* 41:1134-1142, 1992
 43. ABBOUD HE: Growth factors and the mesangium. *J Am Soc Nephrol* 2:S185-S189, 1992
 44. LAN HY, NIKOLIC-PATERSON DJ, ATKINS RC: Immune events in lymphoid tissues during experimental glomerulonephritis. *Pathology* 25:159-166, 1993
 45. FAHERTY DA, CLAUDY V, PLOCINSKI JM, KAFFKA K, KILLIAN P, THOMPSON RC: Failure of IL-1 receptor antagonism to inhibit antigen-specific immune responses in vivo. *J Immunol* 148:766-771, 1992

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)